Grifols SA
Research Grifols SA (GRFS) on Bullrun: valuation model: 54.7% undervalued, market cap USD 2.09B, P/E 10.4, dividend yield 1.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGRFS
- ExchangeNASDAQ
- CountrySpain
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signal54.7% undervalued
- Market capUSD 2.09B
- P/E10.4
- Dividend yield1.2%
- Financial periodQ2 2026
- RevenueEUR 1.87B
- Net incomeEUR 154.00M
- Free cash flowEUR 108.00M
- Gross margin37.6%
Valuation Snapshot
Bullrun's latest valuation model marks Grifols SA as 54.7% undervalued; latest market cap is USD 2.09B; P/E is 10.4; dividend yield is 1.2%.
Peer valuation comparison
Latest P/E is 10.44x versus a Healthcare sector median of 24.46x (57.3% below).
Latest dividend yield is 1.2% versus a Healthcare sector median of 2.11% (43.1% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.09B | 10.4 | 1.2% | 0.09 |
| 2025 | 2025-12-31 | USD 6.36B | 14.0 | 1.8% | 0.17 |
| 2024 | 2024-12-31 | USD 5.06B | 29.8 | n/a | n/a |
| 2023 | 2023-12-29 | USD 7.84B | 32.1 | n/a | n/a |
| 2022 | 2022-12-30 | USD 5.77B | 8.8 | n/a | n/a |
| 2021 | 2021-12-31 | USD 7.62B | 11.6 | 4.1% | 0.46 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.09 USD, yield 1.2%.
About Grifols SA
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Grifols SA overvalued or undervalued?
Bullrun's valuation model currently marks Grifols SA as 54.7% undervalued.
What is Grifols SA's market cap?
Grifols SA's market capitalization is USD 2.09B.
What is Grifols SA's P/E ratio?
Grifols SA's price-to-earnings (P/E) ratio is 10.4.
Does Grifols SA pay a dividend?
Grifols SA has a dividend yield of 1.2%.
What does Grifols SA do?
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.